Skip to content

Abstract 14045: Pulmonary Hypertension Phenotype and Incretin-Based Therapy in CardioMEMS-Guided Heart Failure Management

Nov 2026 · Circulation · 0 citations

TL;DR

In CardioMEMS-guided HF management, IBT use was independently associated with lower 2-year all-cause mortality after adjustment for PH phenotype and propensity score matching, and these findings support further prospective investigation of incretin-based therapies in advanced HF populations.

Abstract

Background: Incretin-based therapies (IBT) reduce major adverse cardiovascular events in diabetes, but their impact on survival in advanced heart failure (HF) managed with invasive hemodynamic monitoring is unknown. Pulmonary hypertension (PH) phenotype at CardioMEMS implantation reflects pulmonary vascular remodeling burden and may identify patients at the highest risk of death despite hemodynamic improvement. Methods: Single-center retrospective analysis of 250 consecutive HF patients undergoing CardioMEMS implantation with 2-year follow-up. The PH phenotype was classified during right heart catheterization (RHC) using the ESC 2022 criteria. The primary outcome was all-cause mortality at 2 years. IBT use included semaglutide (n=44) and tirzepatide (n=16); all users had diabetes. Multivariable Cox regression and 1:2 propensity score matching (PSM), adjusting for age, sex, EF, GFR, BMI, and PH phenotype, were used to evaluate the independent association of IBT with mortality. Results: Among 250 patients (mean age 70.4±11.8 years; 45.6% women), PH distribution was: no PH 20 (8%), pre-capillary PH 56 (22%), isolated post-capillary PH (IpcPH) 90 (36%), and combined pre- and post-capillary PH (CpcPH) 84 (34%). IBT, including semaglutide and tirzepatide, was used in 60 patients (24%) and was distributed evenly across PH phenotypes (p=0.68). Despite the greatest hemodynamic response, CpcPH had the highest 2-year mortality (47.6%). Mean 12-month PAD reduction was similar between IBT users and non-users (–5.5 vs –5.6 mmHg, p=0.80). IBT users had lower 2-year all-cause mortality than non-users (16.4% vs 49.7%). On multivariable Cox regression, IBT was independently associated with lower mortality (HR 0.36, 95% CI 0.19-0.69; p=0.002), confirmed in the PSM cohort (17.3% vs 52.0%; p=0.004). This association was directionally consistent across PH phenotypes (Figure 1). Conclusions: In CardioMEMS-guided HF management, IBT use was independently associated with lower 2-year all-cause mortality after adjustment for PH phenotype and propensity score matching. The highest mortality in CpcPH despite the greatest hemodynamic response suggests that filling pressure reduction alone may not overcome advanced pulmonary vascular remodeling. Similar PAD reduction between IBT users and non-users suggests that this survival association may not be explained solely by hemodynamic improvement. These findings support further prospective investigation of incretin-based therapies in advanced HF populations.

View source

Similar papers

Nov 2026

Abstract 15107: Clinical Features, Hemodynamics and Outcomes of Pulmonary Hypertension in Adults with Congenital Heart Disease and Heart Failure with Reduced Ejection Fraction

Background: Although pulmonary hypertension (PH) and heart failure (HF) with reduced ejection fraction (HFrEF) occur in adults with congenital heart disease (CHD), the relationship between PH and HFrEF has not been systematically studied in this population. We sought to define the clinical characteristics, hemodynam...

Amr Moustafa, Ahmed T. Abdelhalim, Z. Kholeif et al. · 0 citations
Oct 2026

Abstract TH184: Demographic Variation in Cardiorenal Complications Among Patients With Resistant Hypertension and Heart Failure With Preserved Ejection Fraction

Background: Resistant hypertension and heart failure with preserved ejection fraction (HFpEF) frequently coexist, yet the long-term burden of downstream cardiorenal complications, and whether that burden is equally distributed across demographic groups, remains poorly characterized. Decade-long real-world data are n...

Satesh Kumar, Fnu Sugandh, Mahima Khatri et al. · 0 citations
Nov 2026

Abstract 9170: Hypertensive Cardiorenal Mortality Co-Occurring With Heart Failure and End-Stage Renal Disease: A 25-Year National Trends Analysis

Introduction: Hypertension is the leading modifiable risk factor for cardiorenal spectrum, with progression to concurrent heart failure (HF) and end-stage renal disease (ESRD) representing a high-risk phenotype. We used a national database to evaluate temporal trends in hypertensive heart and renal disease mortality...

Kartikeya Srivastava, Ali Zubair, M. Arham et al. · 0 citations
Nov 2026

Abstract 15216: Sodium Glucose Cotransporter-2 Inhibitors in Heart Failure with Reduced Ejection Fraction and Active Malignancy: A Propensity Matched Retrospective Analysis

Background: Patients living with both heart failure with reduced ejection fraction (HFrEF) and active malignancy represent one of the most challenging populations in modern cardiology. Despite carrying the highest combined cardiovascular and oncologic risk, they have been excluded from every landmark sodium glucose...

Satesh Kumar, Fnu Sugandh, Mahima Khatri et al. · 0 citations
Nov 2026

Abstract 15728: Clinical and Hemodynamic Phenotypes of Residual Pulmonary Hypertension After Acute Decompensated Heart Failure Hospitalization

Introduction: Residual pulmonary hypertension (PH) after stabilization from acute decompensated heart failure (ADHF) is common and reflects heterogeneous pathophysiological mechanisms, involving left-sided filling pressures, pulmonary vascular remodeling, right-sided dysfunction, and comorbidity burden. Such heterog...

T. Iwanaga, Y. Shiraishi, S. Kohsaka et al. · 0 citations
Nov 2026

Abstract 10192: Implementation of Kidney-Protective Therapies and Renal Outcomes in Heart Failure with Diabetic Kidney Disease: A Multicenter Cohort Study

Background: Heart failure frequently coexists with diabetic kidney disease (DKD), resulting in substantial cardiorenal risk. Current guidelines recommend kidney-protective therapies including renin-angiotensin system inhibitors or angiotensin receptor-neprilysin inhibitors (RASi/ARNI), sodium-glucose cotransporter-2...

Y. Hoshika, Y. Kubota, T. Nishino et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.